Johns Hopkins Medicine lance un centre majeur de recherche sur les drogues psychédéliques


Translating…


De Beste Kwaliteit CBD Olie?

MHBioShop CBD Olie Specialist  


Pour la meilleure qualité d’Huile de CBD Visitez

HuileCBD.be specialiste Huile de CBD


   

The esteemed research institute and medical school Johns Hopkins Medicine is starting the Center for Psychedelic and Consciousness Research thanks to $17 million in private donations. The generous funders include Boing Boing pal and author Tim Ferriss, WordPress founder Matt Mullenweg, TOMS shoes founder Blake Mycoskie, and investor Craig Nerenberg. Psychedelics have tremendous unlocked therapeutic potential for the likes of severe depression, PTSD, obsessive-compulsive disorder, and alcoholism, What a wonderful, important, and worthy cause these individuals chose to support. From Johns Hopkins Medical:

In 2000, the psychedelic research group at Johns Hopkins was the first to achieve regulatory approval in the U.S. to reinitiate research with psychedelics in healthy volunteers who had never used a psychedelic. Their 2006 publication on the safety and enduring positive effects of a single dose of psilocybin sparked a renewal of psychedelic research worldwide.

Since then, the researchers have published studies in more than 60 peer-reviewed journal articles. Their research has demonstrated therapeutic benefits for people who suffer from conditions including nicotine addiction and depression and anxiety caused by life-threatening diseases such as cancer. It has paved the way for current studies on treatment of major depressive disorder. These researchers have also expanded the field of psychedelic research by publishing safety guidelines that have helped gain approval for psychedelic studies at other universities around the world and by developing new ways of measuring mystical, emotional, and meditative experiences while under the influence of psychedelics.

The group’s findings on both the promise and the risks of psilocybin in particular helped create a path forward for the chemical’s potential medical approval and reclassification from a Schedule I drug, the most restrictive federal government category, to a more appropriate level. Psilocybin was classified as Schedule I during the Nixon administration, but the team’s research over the last decade has shown psilocybin to have low toxicity and abuse potential.

Lees Meer

Leave a Comment